These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27242802)

  • 1. The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs.
    Van Dyke RB; Chadwick EG; Hazra R; Williams PL; Seage GR
    Front Immunol; 2016; 7():199. PubMed ID: 27242802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.
    Williams PL; Crain MJ; Yildirim C; Hazra R; Van Dyke RB; Rich K; Read JS; Stuard E; Rathore M; Mendez HA; Watts DH;
    JAMA Pediatr; 2015 Jan; 169(1):48-55. PubMed ID: 25383770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Utero Antiretroviral Exposure and Risk of Neurodevelopmental Problems in HIV-Exposed Uninfected 5-Year-Old Children.
    Yao TJ; Malee K; Zhang J; Smith R; Redmond S; Rice ML; Frederick T; Torre P; Mellins CA; Hoffman HJ; Williams PL
    AIDS Patient Care STDS; 2023 Mar; 37(3):119-130. PubMed ID: 36827595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
    Williams PL; Yildirim C; Chadwick EG; Van Dyke RB; Smith R; Correia KF; DiPerna A; Seage GR; Hazra R; Crowell CS;
    Lancet HIV; 2020 Jan; 7(1):e49-e58. PubMed ID: 31740351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.
    Williams PL; Hazra R; Van Dyke RB; Yildirim C; Crain MJ; Seage GR; Civitello L; Ellis A; Butler L; Rich K;
    AIDS; 2016 Jan; 30(1):133-44. PubMed ID: 26731758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of risk for late language emergence after in utero antiretroviral drug exposure in HIV-exposed uninfected infants.
    Rice ML; Zeldow B; Siberry GK; Purswani M; Malee K; Hoffman HJ; Frederick T; Buchanan A; Sirois PA; Allison SM; Williams PL;
    Pediatr Infect Dis J; 2013 Oct; 32(10):e406-13. PubMed ID: 24067563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newborn Hearing Screenings in Human Immunodeficiency Virus-Exposed Uninfected Infants.
    Torre P; Zeldow B; Yao TJ; Hoffman HJ; Siberry GK; Purswani MU; Frederick T; Spector SA; Williams PL
    J AIDS Immune Res; 2016; 1(1):. PubMed ID: 28459118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.
    Sirois PA; Huo Y; Williams PL; Malee K; Garvie PA; Kammerer B; Rich K; Van Dyke RB; Nozyce ML;
    Pediatr Infect Dis J; 2013 Jun; 32(6):648-55. PubMed ID: 23340561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study.
    Caniglia EC; Patel K; Huo Y; Williams PL; Kapetanovic S; Rich KC; Sirois PA; Jacobson DL; Hernandez-Diaz S; Hernán MA; Seage GR;
    AIDS; 2016 May; 30(8):1267-78. PubMed ID: 26867136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-trimester exposure to newer antiretroviral agents and congenital anomalies in a U.S. cohort.
    Fung K; Hernandez-Diaz S; Zash R; Chadwick EG; Van Dyke RB; Broadwell C; Jao J; Powis K; Yee LM; Williams PL;
    AIDS; 2024 Jun; ():. PubMed ID: 38864586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acylcarnitine Profiles in HIV-Exposed, Uninfected Neonates in the United States.
    Kirmse B; Yao TJ; Hofherr S; Kacanek D; Williams PL; Hobbs CV; Hazra R; Borkowsky W; Van Dyke RB; Summar M
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):339-48. PubMed ID: 26548585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk for Speech and Language Impairments in Preschool Age HIV-exposed Uninfected Children With In Utero Combination Antiretroviral Exposure.
    Rice ML; Russell JS; Frederick T; Purswani M; Williams PL; Siberry GK; Redmond SM; Hoffman HJ; Yao TJ;
    Pediatr Infect Dis J; 2018 Jul; 37(7):678-685. PubMed ID: 29278615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral Drugs in Meconium: Detection for Different Gestational Periods of Exposure.
    Himes SK; Tassiopoulos K; Yogev R; Huestis MA;
    J Pediatr; 2015 Aug; 167(2):305-11.e3. PubMed ID: 26001315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Utero Exposure to Antiretroviral Drugs: Effect on Birth Weight and Growth Among HIV-exposed Uninfected Children in Brazil.
    Hofer CB; Keiser O; Zwahlen M; Lustosa CS; Frota AC; de Oliveira RH; Abreu TF; Carvalho AW; Araujo LE; Egger M
    Pediatr Infect Dis J; 2016 Jan; 35(1):71-7. PubMed ID: 26741583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood lead levels and neurodevelopmental function in perinatally HIV-exposed, uninfected children in a US-based longitudinal cohort study.
    Tassiopoulos K; Huo Y; Braun J; Williams PL; Smith R; Aschengrau A; Nichols S; Hazra R; Meyer WA; Knapp K; Deygoo NS; Seage Iii GR
    AIDS Res Hum Retroviruses; 2017 Sep; 33(9):919-928. PubMed ID: 28322573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.
    Spaulding AB; Yu Q; Civitello L; Mussi-Pinhata MM; Pinto J; Gomes IM; Alarcón JO; Siberry GK; Harris DR; Hazra R
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):349-56. PubMed ID: 26879281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV exposure through contact with body fluids.
    Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals.
    Knapp KM; Brogly SB; Muenz DG; Spiegel HM; Conway DH; Scott GB; Talbot JT; Shapiro DE; Read JS
    Pediatr Infect Dis J; 2012 Feb; 31(2):164-70. PubMed ID: 21983213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.
    Sibiude J; Le Chenadec J; Bonnet D; Tubiana R; Faye A; Dollfus C; Mandelbrot L; Delmas S; Lelong N; Khoshnood B; Warszawski J; Blanche S;
    Clin Infect Dis; 2015 Jul; 61(2):270-80. PubMed ID: 25838291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.